Abstract
Few therapies are currently available for patients with KRAS-driven cancers, highlighting the need to identify new molecular targets that modulate central downstream effector pathways. Here we found that the microRNA (miRNA) cluster including miR181ab1 is a key modulator of KRAS-driven oncogenesis. Ablation of Mir181ab1 in genetically engineered mouse models of Kras-driven lung and pancreatic cancer was deleterious to tumor initiation and progression. Expression of both resident miRNAs in the Mir181ab1 cluster, miR181a1 and miR181b1, was necessary to rescue the Mir181ab1-loss phenotype, underscoring their nonredundant role. In human cancer cells, depletion of miR181ab1 impaired proliferation and 3D growth, whereas overexpression provided a proliferative advantage. Lastly, we unveiled miR181ab1-regulated genes responsible for this phenotype. These studies identified what we believe to be a previously unknown role for miR181ab1 as a potential therapeutic target in 2 highly aggressive and difficult to treat KRAS-mutated cancers.
Funding Information
  • European Commission (618312 KRASmiR FP7-PEOPLE-2013-CIG)
  • Spanish Ministry of Economy and Competitiveness (SAF2013-46423-R)
  • Worldwide Cancer Research (16-0224)
  • RED TEMATICA DE INVESTIGACION COOPERATIVA EN RED (RD12/0036/0040)
  • PHS Grant (4R01CA129562)
  • National Institutes of Health (R00CA197816,P50CA070907,P30CA016672)
  • National Institutes of Health (1R01AI073724,OD00643501)
  • Spanish Ministry of Economy and Competitiveness (FJCI-2017-34233))
  • Swiss National Science Foundation (P300PB-174377)
  • European Commission (618312 KRASmiR FP7-PEOPLE-2013-CIG)